Imagion to Present Prostate Cancer Research Data at WMIC 2022

Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity……


Ticker News Interview - Breast Cancer Clinical Trial Update

Bob Proulx discusses updates on the first-in-human MagSense® HER2 breast cancer clinical trial with TickerTV - trial is progressing positively.  …


MagSense® HER2 Breast Cancer First-in-human Study Progress Update

Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging…


Bob Proulx Discusses Imagion's Recent Progress with Boardroom Media

Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx…


2019 World Molecular Imaging Conference Poster

This study is the Company's first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion's Magsense™ technology, which provide…


Imagion Biosystems hits key development milestone with initiation of toxicology study

Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the commencement of a toxicology safety study of its lead…


Imagion Biosystems teams with Planet Innovation for MagSense® Instrument Development

Click to view press release on PR/Newswire MELBOURNE, Australia, Dec. 17, 2018 /PRNewswire/ -- Imagion Biosystems Limited (ASX: IBX), a company dedicated to…


MagSense® Pre-Clinical Study Presented at 2018 SABCS

On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…


MagSense Technology Animation

. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense®…


Perspectives on X-Ray Imaging

This article represents the viewpoint of management. When MagSense technology reaches the clinic, it will join a distinguished pantheon of time-honored cancer…